$603 Million is the total value of Cormorant Asset Management, LP's 71 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GLPG | GALAPAGOS NVspon adr | $22,918,000 | -12.1% | 300,000 | 0.0% | 3.80% | +0.4% | |
| PTI | PROTEOSTASIS THERAPEUTICS IN | $17,803,000 | -40.2% | 3,804,027 | 0.0% | 2.95% | -31.7% | |
| CLSD | CLEARSIDE BIOMEDICAL INC | $17,681,000 | +14.7% | 1,940,880 | 0.0% | 2.93% | +31.0% | |
| EGRX | EAGLE PHARMACEUTICALS INC | $15,778,000 | -4.9% | 200,000 | 0.0% | 2.62% | +8.6% | |
| GEMP | GEMPHIRE THERAPEUTICS INC | $12,282,000 | +22.8% | 952,798 | 0.0% | 2.04% | +40.1% | |
| CHRS | COHERUS BIOSCIENCES INC | $8,901,000 | -32.2% | 620,300 | 0.0% | 1.48% | -22.6% | |
| ARRY | ARRAY BIOPHARMA INC | $7,533,000 | -6.4% | 900,000 | 0.0% | 1.25% | +6.9% | |
| SGYPQ | SYNERGY PHARMACEUTICALS INC | $5,340,000 | -4.5% | 1,200,000 | 0.0% | 0.88% | +9.0% | |
| CFRX | CONTRAFECT CORP | $5,148,000 | -19.4% | 3,550,000 | 0.0% | 0.85% | -8.1% | |
| DXCM | DEXCOM INC | $5,121,000 | -13.7% | 70,000 | 0.0% | 0.85% | -1.4% | |
| DERM | DERMIRA INC | $4,954,000 | -14.6% | 170,000 | 0.0% | 0.82% | -2.5% | |
| FLGT | FULGENT GENETICS INC | $4,793,000 | -41.5% | 750,000 | 0.0% | 0.79% | -33.2% | |
| AGEN | AGENUS INC | $4,692,000 | +3.7% | 1,200,000 | 0.0% | 0.78% | +18.4% | |
| AGRX | AGILE THERAPEUTICS INC | $4,688,000 | +17.0% | 1,250,000 | 0.0% | 0.78% | +33.5% | |
| INTEC PHARMA LTD JERUSALEM | $4,616,000 | +11.5% | 809,804 | 0.0% | 0.76% | +27.3% | ||
| CRIS | CURIS INC | $3,780,000 | -32.0% | 2,000,000 | 0.0% | 0.63% | -22.3% | |
| COLL | COLLEGIUM PHARMACEUTICAL INC | $3,753,000 | +24.4% | 300,000 | 0.0% | 0.62% | +42.0% | |
| CTMX | CYTOMX THERAPEUTICS INC | $3,565,000 | -10.2% | 230,000 | 0.0% | 0.59% | +2.4% | |
| SRNE | SORRENTO THERAPEUTICS INC | $3,382,000 | -49.4% | 1,690,800 | 0.0% | 0.56% | -42.2% | |
| IMDZ | IMMUNE DESIGN CORP | $3,286,000 | +43.4% | 337,000 | 0.0% | 0.54% | +63.7% | |
| LPCN | LIPOCINE INC NEW | $2,981,000 | +3.1% | 741,496 | 0.0% | 0.49% | +17.6% | |
| AAAP | ADVANCED ACCELERATOR APPLICsponsored ads | $2,928,000 | -2.1% | 75,000 | 0.0% | 0.48% | +11.8% | |
| ABEO | ABEONA THERAPEUTICS INC | $2,560,000 | +28.0% | 400,000 | 0.0% | 0.42% | +46.2% | |
| RGNX | REGENXBIO INC | $2,370,000 | +2.3% | 120,000 | 0.0% | 0.39% | +17.0% | |
| PFNX | PFENEX INC | $2,306,000 | -31.0% | 574,966 | 0.0% | 0.38% | -21.2% | |
| XLRN | ACCELERON PHARMA INC | $2,279,000 | +14.8% | 75,000 | 0.0% | 0.38% | +31.2% | |
| XNCR | XENCOR INC | $1,583,000 | -11.8% | 75,000 | 0.0% | 0.26% | +0.8% | |
| APTOSE BIOSCIENCES INC | $1,218,000 | +20.6% | 990,579 | 0.0% | 0.20% | +37.4% | ||
| MYOV | MYOVANT SCIENCES LTD | $1,170,000 | -0.3% | 100,000 | 0.0% | 0.19% | +14.1% | |
| ONS | ONCOBIOLOGICS INC | $1,013,000 | -62.3% | 1,002,516 | 0.0% | 0.17% | -56.9% | |
| HTGM | HTG MOLECULAR DIAGNOSTICS IN | $541,000 | -61.6% | 203,464 | 0.0% | 0.09% | -55.9% | |
| NEOS | NEOS THERAPEUTICS INC | $369,000 | +1.4% | 50,613 | 0.0% | 0.06% | +15.1% | |
| THLD | THRESHOLD PHARMACEUTICAL INC | $354,000 | -31.0% | 900,000 | 0.0% | 0.06% | -20.3% | |
| CLRB | CELLECTAR BIOSCIENCES INC | $87,000 | -28.7% | 53,649 | 0.0% | 0.01% | -22.2% | |
| ONSIW | ONCOBIOLOGICS INC*w exp 02/18/201 | $72,000 | -78.4% | 416,666 | 0.0% | 0.01% | -75.0% | |
| ONSIZ | ONCOBIOLOGICS INC*w exp 05/18/201 | $39,000 | -81.2% | 416,666 | 0.0% | 0.01% | -80.0% | |
| CLRBW | CELLECTAR BIOSCIENCES INC*w exp 08/20/201 | $12,000 | -40.0% | 52,999 | 0.0% | 0.00% | -33.3% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-13 |
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.